Experts urge clinicians to focus on stroke prevention benefits when counseling patients about carotid revascularization.
Mavacamten (Camzyos) is now approved by the US Food and Drug Administration for use not only in adults, but also in pediatric patients with obstructive hypertrophic cardiomyopathy (HCM) who weigh at ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results